FMP

FMP

Enter

LEXX - Lexaria Bioscience C...

Financial Summary of Lexaria Bioscience Corp.(LEXX), Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology,

photo-url-https://financialmodelingprep.com/image-stock/LEXX.png

Lexaria Bioscience Corp.

LEXX

NASDAQ

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

2.2 USD

-0.04 (-1.82%)

About

ceo

Mr. Christopher A. Bunka

sector

Healthcare

industry

Biotechnology

website

https://www.lexariabioscience.com

exchange

NASDAQ

Description

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectiv...

CIK

0001348362

ISIN

US52886N4060

CUSIP

52886N406

Address

100 – 740 McCurdy Road

Phone

250 765 6424

Country

CA

Employee

5

IPO Date

Jan 12, 2021

Summary

CIK

0001348362

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

52886N406

ISIN

US52886N4060

Country

CA

Price

2.2

Beta

0.92

Volume Avg.

493.88k

Market Cap

27.23M

Shares

-

52-Week

0.649-6.85

DCF

-1.45

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.62

P/B

-

Website

https://www.lexariabioscience.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest LEXX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep